---
document_datetime: 2023-09-21 18:32:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_en.pdf
document_name: novothirteen-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6732603
conversion_datetime: 2025-12-23 03:10:50.31634
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU number       | Invented name   | Strength   | Pharmaceutical Form                           | Route of administration   | Immediate Packaging                         | Content (concentration)          | Pack size                                       |
|-----------------|-----------------|------------|-----------------------------------------------|---------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| EU/1/12/775/001 | NovoThirteen    | 2500 IU    | Powder and solvent for solution for injection | Intravenous use           | powder: vial (glass); solvent: vial (glass) | powder: 2500 IU; solvent: 3.2 ml | 1 powder vial + 1 solvent vial + 1 vial adapter |